None listed
Conditions
Interventions
Dietary Supplement : Test group: Oral intake of 1 capsule once a day
Curcuma longa extract extract powder 250mg/1day
Total intake period 84 days (12 weeks)
Contro
Sponsors
Wonkwang University. Iksan Korean Medicine Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) A person between the ages of 50 and 85 as of the date of consent 2) A person complaining memory degradation [scored 1~5 of Subjective Memory Complaints Questionnaire(SMCQ)] 3) A person with a standard score of 86 or higher for the Korean version of Memory Assessment Scales(K-MAS) 4) A person who is not matched to the clinical diagnostic criteria of Attention Deficit Hyperactivity Disorder (ADHD) 5) A person who voluntarily decides to participate in this clinical trial and agrees in writing to comply with the precautions after fully understanding the explanation of this human study.
Exclusion criteria
Exclusion criteria: 1) A person who has taken the following drugs within 4 weeks of the date of consent - Anti-dementia drugs, neuroprotective agents, thyroid hormone drugs, CNS stimulants, antipsychotic, or anticholinergic 2) A person who shows abnormalities on a blood test - over 3 times compared to the upper limit of normal levels for ALT and AST - over 3 times compared to the upper limit of normal levels for Serum Creatinine or a chronic or acute renal failure patient 3) A patient who has a cognitive impairment due to brain disease or mental disease 4) A person who has been diagnosed with hypertension, diabetes mellitus, or hypothyroidism which cannot be controlled with medication 5) A person who has severe mental diseases, such as severe depression, schizophrenia, alcoholism, or drug intoxication 6) A person with a history of percutaneous coronary intervention including unstable angina pectoris, myocardial infarction, transient ischemic attacks and coronary artery bypass surgery within 6 months of the date of consent 7) A person with a history of severe head injury with loss of consciousness within 6 months of the date of consent 8) A person with a history of acute stroke within 3 months of the date of consent 9) A person who has taken another human study drug within 3 months 10) A person who has taken or is currently taking any health functional food related to the relevant function in this study within 3 months from the start of the test 11) A person who has hypersensitive reactions to the functional food of this study 12) A patient with severe disability in hearing or visual impairment who cannot conduct efficacy assessments 13) A person who cannot be judged as a suitable participant of this study because of having conditions which can influence the result of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Kims Frontal-Executive Neuropsychological Test | — |
Secondary
| Measure | Time frame |
|---|---|
| Korean version of Memory Assessment Scale (K-MAS);Blood Test;Blood Chemistry Test;Lipid Test;Urinalysis | — |
Countries
Korea, Republic of
Contacts
Public ContactJung Han Lee
Wonkwang University. Iksan Korean Medicine Hospital
Outcome results
None listed